Dynavax Technologies (DVAX) Leaps on FDA Cancellation

Dynavax Technologies Corporation

shares gained 24.9% from Friday to $13.63, after the U.S. Food and Drug Administration cancelled its upcoming ADCOM meeting, where it would decide if the company's Heplisav drug would be approved or not. Share volume was 6.3 million, towering an all-day average of 800,000